Roxee Meds Catalog

Clindamycin

Medication catalog facts with explicit FDA-approval, off-label, source-limited, and safety context.

Both Catalog complete FDA data linked Rx required Capsule Multiple FDA labelers Official label facts Owner quick guide first

Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Storefront facts

Catalog refreshed

May 5, 2026, 10:00 a.m.

These are the storefront facts Roxee uses on browse cards and quick facts.

FDA applications

FDA application data refreshed

May 5, 2026, 10:00 a.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports

Safety data refreshed

May 5, 2026, 10:01 a.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details

Storefront facts: Source Roxee | Refreshed May 5, 2026, 10:00 AM UTC
The storefront fact projection used for browse cards and quick facts.
Animal Drugs @ FDA: Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
Applications/products are imported from FDA export data.
Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC

Evidence

Reviewed / Updated / Sources

Reviewed by: Not available

Last reviewed: February 12, 2026

Updated: February 12, 2026, 10:44 PM UTC

Sources:

FDA application profile · official_label
FDA application profile · official_label
Medication usage source · fda_animal_drugs
ClindaMed™ Oral Drops · official_label
openFDA case USA-USFDACVM-2025-US-070095 · adverse_reaction

Image coming soon

Clindamycin

Drug type: Generic ingredient • Branded profile • FDA branded products available

Both Capsule Rx required 100% storefront ready

Species: Both

Manufacturer: Multiple FDA labelers

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Clindamycin

For the treatment of skin infections (wounds and abscesses) due to susceptible strains of coagulase-positive staphylococci ( Staphylococcus aureus or S. intermedius ), deep wounds and abscesses due to susceptible strains of Bacteroides fragilis , Prevotella melaninogenicus , Fusobacterium necrophorum , and Clostridium perfringens , dental infections due to susceptible strains of S. aureus , B. fragilis , P. melaninogenicus , F. necrophorum , and C. perfringens , and osteomyelitis due to susceptible strains of S. aureus , B. fragilis , P. melaninogenicus , F. necrophorum , and C. perfringens . For the treatment of skin infections (wounds and abscesses) due to susceptible strains of coagulase-positive staphylococci ( Staphylococcus aureus or S. intermedius ), deep wounds and abscesses due to susceptible strains of Bacteroides fragilis , Prevotella melaninogenicus, Fusobacterium necrophorum , and Clostridium perfringens , dental infections due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens , and osteomyelitis due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum , and C. perfringens . For the treatment of skin infections (wounds and abscesses) due to susceptible strains of S. aureus, S. intermedius, Streptococcus species, deep wounds and abscesses due to susceptible strains of Clostridium perfringens and Bacteroides fragilis , and dental infections due to susceptible strains of S. aureus, S. intermedius, Streptococcus species, C. perfringens , and B. fragilis . Species commonly shown: Both, Dog, No Use Class Stated Or Implied, Cat, No Use Class Stated Or Implied.

Generic name

Clindamycin

Brand names

Antirobe® Capsules, Antirobe Aquadrops®, Clindamycin Hydrochloride Oral Liquid, Clinsol®

Manufacturer

Multiple FDA labelers

Species

Both, Dog, No Use Class Stated Or Implied, Cat, No Use Class Stated Or Implied

Dosage forms

Capsule, Liquid (Solution), Tablet, Liquid

Prescription

Prescription required

Completeness

100%

Validation

Complete

Brand names

Antirobe® Capsules Antirobe Aquadrops® Clindamycin Hydrochloride Oral Liquid Clinsol® Clindamycin Hydrochloride Capsules Clintabs® ClindaRobe™ Clindamycin Hydrochloride Oral Drops ClindaMed™ Oral Drops Clindamycin Hydrochloride Tablets Clindamycin Clindamycin Hydrochloride CLINTABS Antirobe Aquadrops Antirobe ZydaClin

Dosage forms

Capsule Liquid (Solution) Tablet Liquid

Indications / Uses

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian

Side Effects

Top reported reactions (openFDA): Vomiting, Death by euthanasia, Lethargy (see also Central nervous system depression in 'Neurological'), Anorexia, Other abnormal test result NOS, Lack of efficacy - NOS.

FAQ

Both, Dog, No Use Class Stated Or Implied, Cat, No Use Class Stated Or Implied

Yes. Roxee shows this as prescription-only.

Capsule, Liquid (Solution), Tablet, Liquid

Related Conditions

Abscesses (cat bite abscess) Osteomyelitis (infectious)

Source Transparency

Verified source: https://www.roxee.ai/meds/
Verified source: https://animaldrugsatfda.fda.gov
Verified source: https://animaldrugsatfda.fda.gov/adafda/views/#/search
Verified source: https://api.fda.gov/animalandveterinary/event.json
Verified source: https://www.roxee.ai/conditions/
Verified source: https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/412
Last refreshed: May 5, 2026, 10:00 a.m.
Last verified: Feb 12, 2026, 10:44 p.m.
Validation status: Complete

Add to My Pet's Meds

Choose a pet, confirm current or past, and optionally add reminder notes.

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

Vomiting (1 reports)
Loss of appetite (1 reports)
Epidermal collarette (1 reports)

When to call the vet:

Repeated vomiting or diarrhea.
Severe lethargy (hard to wake, very low energy).
Collapse or fainting.
Trouble breathing.
Facial swelling or hives.
Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to tell or ask your vet today:

Is this medicine the right fit for my pet’s current symptoms?
Which warning signs mean I should call back right away?
How should I handle missed doses or refusal to take the medicine?

Major cautions & emergency warning signs

Side effects to monitor:

Vomiting
Loss of appetite
Epidermal collarette

Most reported reactions:

Vomiting (1 reports)
Loss of appetite (1 reports)
Epidermal collarette (1 reports)

Emergency warning signs:

Repeated vomiting or diarrhea.
Severe lethargy (hard to wake, very low energy).
Collapse or fainting.
Trouble breathing.

Talk to a Vet / Find a Vet Near You Start Symptom Intake

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both

Manufacturer: Multiple FDA labelers

Form: Capsule, Liquid, Liquid (Solution), Tablet

Identifiers:

ANADA: 200193 ANADA: 200291 ANADA: 200298 ANADA: 200316 ANADA: 200383 ANADA: 200398 ANADA: 200538 ANADA: 200813 NADA: 120161 NADA: 135940 NDC Package: 13985-957-25 NDC Package: 51311-400-40 NDC Package: 51311-402-75 NDC Package: 51311-404-15 NDC Package: 54771-3043-1 NDC Package: 54771-3044-1 NDC Package: 54771-3045-1 NDC Package: 54771-3179-1 NDC Package: 54771-3179-2 NDC Package: 69043-013-20

Source metadata:

https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/200813 · official_label · FDA application profile
https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/120161 · official_label · FDA application profile
https://animaldrugsatfda.fda.gov · fda_animal_drugs · Medication usage source

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian

High: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian

Source metadata:

https://animaldrugsatfda.fda.gov · fda_animal_drugs · Contraindication source

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals

Reported cases

Serious reports

Species represented

Grouped by Body System

Digestive (5) · Vomiting, Loss of appetite, Drooling Skin & allergy (1) · Application site hair loss Behavior (1) · Behavioral disorder (unspecified) Other (25) · Epidermal collarette, Elevated total bilirubin, Elevated serum alkaline phosphatase

Most Reported Reactions

Body system	Cases	Species	Serious cases
Digestive	1	Dog	1
Digestive	1	Dog	1
Other	1	Dog	1
Other	1	Dog	1
Other	1	Dog	1
Other	1	Dog	1
Other	1	Dog	1
Other	1	Dog	1

Species coverage: Dog (26) Cat (6)

View detailed reaction table

Body system	Species	Seriousness	Frequency	Reports
Digestive	Dog	Serious	-	1
Digestive	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Non-serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Digestive	Dog	Serious	-	1
Other	Cat	Serious	-	1
Digestive	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Digestive	Dog	Serious	-	1
Other	Cat	Serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Behavior	Dog	Serious	-	1
Skin & allergy	Cat	Non-serious	-	1
Other	Cat	Non-serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1

Source metadata:

https://api.fda.gov/animalandveterinary/event.json · adverse_reaction · openFDA case USA-USFDACVM-2025-US-070095

Documents

Owner handouts and official technical documents open on-page first, with the original source still one click away.

Owner handouts

No owner handouts linked yet.

Official label / PI

No official label or package insert links yet.

SPL

FOI

Clindamycin Hydrochloride Tablets

SPL · SPL

Open original

FDA Structured Product Label

Clindamycin Hydrochloride Tablets

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Felix Pharmaceuticals Pvt. Ltd.
ANADA: 200-813
Status: RX
Form: Tablet
Route: Oral

Composition / specifications

25 mg, 75 mg, and 150 mg

Dogs

Indication

For the treatment of skin infections (wounds and abscesses) due to susceptible strains of coagulase-positive staphylococci (Staphylococcus aureus or S. intermedius), deep wounds and abscesses due to susceptible strains of Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum, and Clostridium perfringens, dental infections due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens, and osteomyelitis due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens.

Dosage

Wounds, abscesses, and dental infections: 2.5 to 15 mg per pound (/lb) body weight every 12 hours for a maximum of 28 days. Osteomyelitis: 5.0 to 15 mg/lb body weight every 12 hours for a minimum of 28 days.

Antirobe® Capsules

SPL · SPL

Open original

FDA Structured Product Label

Antirobe® Capsules

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Zoetis Inc.
NADA: 120-161
Status: RX
Form: Capsule
Route: Oral
Species: Dog, No Use Class Stated Or Implied

Composition / specifications

Each capsule contains the equivalent of 25, 75, 150 or 300 milligrams of clindamycin as the hydrated hydrochloride salt.

Dogs

Indication

For the treatment of skin infections (wounds and abscesses) due to susceptible strains of coagulase-positive staphylococci (Staphylococcus aureus or S. intermedius), deep wounds and abscesses due to susceptible strains of Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum, and Clostridium perfringens, dental infections due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens, and osteomyelitis due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens.

Dosage

Wounds, abscesses, and dental infections: 2.5 to 15 milligrams per pound of body weight every 12 hours for a maximum of 28 days. Osteomyelitis: 5.0 to 15 milligrams per pound of body weight every 12 hours for a minimum of 28 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

ClindaMed™ Oral Drops

SPL · SPL

Open original

FDA Structured Product Label

ClindaMed™ Oral Drops

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Bimeda Animal Health Limited
ANADA: 200-538
Status: RX
Form: Liquid
Route: Oral
Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied

Composition / specifications

Each mL contains clindamycin hydrochloride equivalent to 25 mg clindamycin.

Dogs

Indication

For the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below:

Skin infections (wounds and abscesses) due to coagulase positive staphylococci (Staphylococcus aureus or Staphylococcus intermedius). Deep wounds and abscesses due to Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens.

Dental infections due to Staphylococcus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens.

Osteomyelitis due to Staphylococcus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens.

Dosage

Wounds, abscesses, and dental infections: 2.5 to 15 mg per pound body weight every 12 hours for a maximum of 28 days.

Osteomyelitis: 5.0 to 15 mg/lb body weight every 12 hours for a minimum of 28 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian

Cats

Indication

Skin infections (wounds and abscesses) due to Staphylococcus aureus, Staphylococcus intermedius, Streptococcus spp. Deep wounds and abscesses due to Clostridium perfringens and Bacteroides fragilis.

Dental infections due to Staphylococcus aureus, Staphylococcus intermedius, Streptococcus spp., Clostridium perfringens and Bacteroides fragilis.

Dosage

5.0 to 15.0 mg/lb body weight every 24 hours for a maximum of 14 days

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian

Clindamycin Hydrochloride Oral Drops

SPL · SPL

Open original

FDA Structured Product Label

Clindamycin Hydrochloride Oral Drops

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: First Priority, Inc.
ANADA: 200-398
Status: RX
Form: Liquid (Solution)
Route: Oral
Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied

Composition / specifications

Each milliliter of solution contains the equivalent of 25 milligrams (mg) clindamycin as the hydrochloride salt.

Dogs

Indication

Dosage

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Cats

Indication

For the treatment of skin infections (wounds and abscesses) due to susceptible strains of S. aureus, S. intermedius, Streptococcus species, deep wounds and abscesses due to susceptible strains of Clostridium perfringens and Bacteroides fragilis, and dental infections due to susceptible strains of S. aureus, S. intermedius, Streptococcus species, C. perfringens, and B. fragilis

Dosage

5.0 to 15.0 milligrams per pound of body weight every 24 hours for a maximum of 14 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Antirobe Aquadrops®

SPL · SPL

Open original

FDA Structured Product Label

Antirobe Aquadrops®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Zoetis Inc.
NADA: 135-940
Status: RX
Form: Liquid (Solution)
Route: Oral
Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied

Composition / specifications

Each milliliter of solution contains the equivalent of 25 milligrams (mg) clindamycin as the hydrochloride salt.

Dogs

Indication

For the treatment of skin infections (wounds and abscesses) due to susceptible strains of coagulase-positive staphylococci (Staphylococcus aureus or S. intermedius), deep wounds and abscesses due to susceptible strains of Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum, and Clostridium perfringens, dental infections due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens, and osteomyelitis due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens.

Dosage

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Cats

Indication

For the treatment of skin infections (wounds and abscesses) due to susceptible strains of S. aureus, S. intermedius, Streptococcus species, deep wounds and abscesses due to susceptible strains of Clostridium perfringens and Bacteroides fragilis, and dental infections due to susceptible strains of S. aureus, S. intermedius, Streptococcus species, C. perfringens, and B. fragilis.

Dosage

5.0 to 15.0 milligrams per pound of body weight every 24 hours for a maximum of 14 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Clindamycin Hydrochloride Oral Liquid

SPL · SPL

Open original

FDA Structured Product Label

Clindamycin Hydrochloride Oral Liquid

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Cronus Pharma Specialities India Private Ltd.
ANADA: 200-193
Status: RX
Form: Liquid (Solution)
Route: Oral
Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied

Composition / specifications

Each milliliter of 8.64 percent alcoholic solution contains the equivalent of 25 milligrams of clindamycin (as the hydrochloride).

Cats

Indication

Aerobic bacteria: Treatment of soft tissue infections (wounds and abscesses) and dental infections caused by or associated with susceptible strains of Staphylococcus aureus, S. intermedius, and Streptococcus species Anaerobic bacteria: Treatment of soft tissue infections (deep wounds and abscesses) and dental infections caused by or associated with susceptible strains of Clostridium perfringens and Bacteroides fragilis.

Dosage

5.0 to 10.0 milligrams per pound of body weight every 24 hours for a maximum of 14 days (11 to 22 milligrams per kilogram of body weight per day).

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Dogs

Indication

For treatment of osteomyelitis caused by susceptible strains of Staphylococcus aureus, and osteomyelitis caused by or associated with susceptible strains of Bacteroides fragilis, Bacteroides melaninogenicus, Fusobacterium necrophorum, and Clostridium perfringens.

Dosage

Osteomyelitis: 5.0 milligrams per pound of body weight every 12 hours for a minimum of 28 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Indication

For use in dogs for treatment of soft tissue infections (wounds and abscesses) and dental infections caused by susceptible strains of Staphylococcus aureus and for soft tissue infections (deep wounds and abscesses) and dental infections caused by or associated with susceptible strains of Bacteroides fragilis, Bacteroides melaninogenicus, Fusobacterium necrophorum, and Clostridium perfringens.

Dosage

Wounds abscesses, and dental infections: 2.5 milligrams per pound of body weight every 12 hours for a maximum of 28 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Clindamycin Hydrochloride Capsules

SPL · SPL

Open original

FDA Structured Product Label

Clindamycin Hydrochloride Capsules

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Cronus Pharma Specialities India Private Ltd.
ANADA: 200-298
Status: RX
Form: Capsule
Route: Oral
Species: Dog, No Use Class Stated Or Implied

Composition / specifications

Each capsule contains the equivalent of 25, 75, or 150 milligrams of clindamycin as the hydrated hydrochloride salt.

Dogs

Indication

Dosage

Wounds, abscesses, and dental infections: 2.5 milligrams per pound of body weight every 12 hours for a maximum of 28 days. Osteomyelitis: 5.0 milligrams per pound of body weight every 12 hours for a minimum of 28 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

ClindaRobe™

SPL · SPL

Open original

FDA Structured Product Label

ClindaRobe™

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Teva Canada Ltd.
ANADA: 200-383
Status: RX
Form: Capsule
Route: Oral
Species: Dog, No Use Class Stated Or Implied

Composition / specifications

<span style="font-size: 10.5pt; font-family: Verdana; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA; mso-bidi-font-family: 'Times New Roman'">Each capsule contains the equivalent of 25, 75, or 150 mg of clindamycin.

Dogs

Indication

For the treatment of skin infections (wounds and abscesses) due to susceptible strains of coagulase-positive staphylococci (Staphylococcus aureus or S. intermedius), deep wounds and abscesses due to susceptible strains of Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum, and Clostridium perfringens, dental infections due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens, and osteomyelitis due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens.

Dosage

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Clinsol®

SPL · SPL

Open original

FDA Structured Product Label

Clinsol®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Virbac AH, Inc.
ANADA: 200-291
Status: RX
Form: Liquid (Solution)
Route: Oral
Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied

Composition / specifications

Each milliliter of solution contains the equivalent of 25 milligrams (mg) clindamycin as the hydrochloride salt.

Dogs

Indication

For the treatment of skin infections (wounds and abscesses) due to susceptible strains of coagulase-positive staphylococci (Staphylococcus aureus or (S. intermedius), deep wounds and abscesses due to susceptible strains of (Bacteroides fragilis, (Prevotella melaninogenicus, (Fusobacterium necrophorum, and (Clostridium perfringens; dental infections due to susceptible strains of (S. aureus, (B. fragilis, (P. melaninogenicus, (F. necrophorum, and (C. perfringens; and osteomyelitis due to susceptible strains of (S. aureus, (B. fragilis, (P. melaninogenicus, (F. necrophorum, and (C. perfringens.

Dosage

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Cats

Indication

For the treatment of skin infections (wounds and abscesses) due to susceptible strains of Staphylococcus aureus, S. intermedius, Streptococcus spp.; deep wounds and abscesses due to susceptible strains of Clostridium perfringens and Bacteroides fragilis; and dental infections due to susceptible strains of S. aureus, S. intermedius, Streptococcus spp., C. perfringens, and B. fragilis.

Dosage

5.0 to 15.0 milligrams per pound of body weight every 24 hours for a maximum of 14 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Clintabs®

SPL · SPL

Open original

FDA Structured Product Label

Clintabs®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Virbac AH, Inc.
ANADA: 200-316
Status: RX
Form: Tablet
Route: Oral
Species: Dog, No Use Class Stated Or Implied

Composition / specifications

Each tablet contains the equivalent of 25, 75 or 150 milligrams of clindamycin as the hydrochloride salt.

Dogs

Indication

For the treatment of skin infections (wounds and abscesses) due to susceptible strains of coagulase-positive staphylococci (Staphylococcus aureus or S. intermedius), deep wounds and abscesses due to susceptible strains of Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum, and Clostridium perfringens, dental infections due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens, and osteomyelitis due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens.

https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/17171 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/17488/Clindamycin%20Hydrochloride%20Tablets · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/380 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/1741/Antirobe%C2%AE%20Capsules · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/1226 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/1777/ClindaMed%E2%84%A2%20Oral%20Drops · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/1143 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/210/Clindamycin%20Hydrochloride%20Oral%20Drops · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/411 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/412 · document · FOI

Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness

Storefront facts: Source Roxee | Refreshed May 5, 2026, 10:00 AM UTC
The storefront fact projection used for browse cards and quick facts.
Animal Drugs @ FDA: Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
Applications/products are imported from FDA export data.
Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC

Official (FDA)

Identity: Generic ingredient • FDA branded products available

Official FDA brands: Antirobe Antirobe Aquadrops CLINTABS Clindamycin Clindamycin Hydrochloride ZydaClin

Manufacturer mapping: Multiple FDA labelers

Case-reported brands (openFDA): MSK

Catalog species: Both • FDA-labeled species: Cat, Dog

Rx/OTC: RX

Form/route: Capsule, Liquid, Liquid (Solution), Tablet • Oral

Applications: ANADA 200-813 • NADA 120-161 • ANADA 200-538 • ANADA 200-398 • NADA 135-940 • ANADA 200-193 • ANADA 200-298 • ANADA 200-383 • ANADA 200-291 • ANADA 200-316

NDC: Packages 13985-957-25 51311-400-40 51311-402-75 51311-404-15 54771-3043-1 54771-3044-1 • Products 13985 51311 54771 69043 86101 86136

Documents: 15 (FOI: 15) • SPL: 10 • Label highlights • Official documents

Safety (openFDA)

Top reactions: Dog 50 • Cat 14 • View

Case summaries: 10 (showing 8) • View

openFDA reports are unverified and do not prove causation.

Explore

Related conditions: Abscesses (cat bite abscess) Osteomyelitis (infectious)

Linked using: Fda_Label (0.95), Fda_Label (0.95)

Diagnosis Codes

Diagnosis-code mappings are not available for this medication yet.

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian (Contraindication, High)

Top reaction signals

Vomiting (1) Loss of appetite (1) Epidermal collarette (1) Elevated total bilirubin (1) Elevated serum alkaline phosphatase (1) Elevated liver enzymes NOS (1) Elevated globulins (1) Elevated alanine aminotransferase (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers

Package NDC	Product NDC	Status
13985-957-25	13985	-
51311-400-40	51311	-
51311-402-75	51311	-
51311-404-15	51311	-
54771-3043-1	54771	-
54771-3044-1	54771	-
54771-3045-1	54771	-
54771-3179-1	54771	-
54771-3179-2	54771	-
69043-013-20	69043	-
69043-014-20	69043	-
69043-015-01	69043	-
69043-015-05	69043	-
69043-016-01	69043	-
86101-052-18	86101	-
86101-053-15	86101	-
86101-054-11	86101	-
86136-147-03	86136	-
86136-148-03	86136	-

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

Clindamycin Hydrochloride SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Clindamycin Hydrochloride SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
CLINTABS SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Antirobe SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Antirobe Aquadrops SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
ZydaClin SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Clindamycin SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
FOI Summary oA 200-813 Approved June 27, 2025.pdf • FOI summary • Official • July 1, 2025
FDA FOI summary for application 200813
ucm069817.pdf • FOI summary • Official • Dec. 10, 2019
FDA FOI summary for application 120161
UCM355629.pdf • FOI summary • Official • Oct. 2, 2018
FDA FOI summary for application 200538
ucm061348.pdf • FOI summary • Official • Dec. 27, 2017
FDA FOI summary for application 200398
N135940_Supp_11_16_89(2).pdf • FOI summary • Official • July 11, 2017
FDA FOI summary for application 135940
UCM454278.pdf • FOI summary • Official • July 11, 2017
FDA FOI summary for application 135940
ucm069874.pdf • FOI summary • Official • July 11, 2017
FDA FOI summary for application 135940
A200193_Org_8_1_1997.pdf • FOI summary • Official • May 22, 2017
FDA FOI summary for application 200193
UCM061609.pdf • FOI summary • Official • May 22, 2017
FDA FOI summary for application 200193
UCM061610.pdf • FOI summary • Official • May 22, 2017
FDA FOI summary for application 200193
ucm061338.pdf • FOI summary • Official • June 1, 2016
FDA FOI summary for application 200383
ucm061770.pdf • FOI summary • Official • June 1, 2016
FDA FOI summary for application 200316
ucm061742.pdf • FOI summary • Official • June 1, 2016
FDA FOI summary for application 200298
ucm061743.pdf • FOI summary • Official • June 1, 2016
FDA FOI summary for application 200298
ucm061719.pdf • FOI summary • Official • June 1, 2016
FDA FOI summary for application 200291

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 57 Clinical 1 Manufacturer 0 Marketing 0

Current Field Facts

side_effects: Top reported reactions (openFDA): Vomiting, Death by euthanasia, Lethargy (see also Central nervous system depression in 'Neurological'), Anorexia, Other abnor… (Clinical, 2026-04-11)
contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed v… (Official, 2026-04-12)
contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed v… (Official, 2026-04-11)
contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed v… (Official, 2026-02-12)
indications: CLINDAROBE Capsules is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions list… (Official, 2026-05-05)
indications: CLINDAROBE Capsules is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions list… (Official, 2026-05-03)
indications: CLINDAROBE Capsules is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions list… (Official, 2026-05-02)
indications: CLINDAROBE Capsules is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions list… (Official, 2026-04-29)
indications: CLINDAROBE Capsules is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions list… (Official, 2026-04-28)
indications: CLINDAROBE Capsules is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions list… (Official, 2026-04-27)
indications: CLINDAROBE Capsules is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions list… (Official, 2026-04-26)
indications: CLINDAROBE Capsules is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions list… (Official, 2026-04-25)
indications: CLINDAROBE Capsules is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions list… (Official, 2026-04-22)
manufacturer_name: Multiple FDA labelers (Official, 2026-05-05)
manufacturer_name: Multiple FDA labelers (Official, 2026-05-03)
manufacturer_name: Multiple FDA labelers (Official, 2026-05-02)
manufacturer_name: Multiple FDA labelers (Official, 2026-04-29)
manufacturer_name: Multiple FDA labelers (Official, 2026-04-28)
manufacturer_name: Multiple FDA labelers (Official, 2026-04-27)
manufacturer_name: Multiple FDA labelers (Official, 2026-04-26)

Recent Revisions

side_effects updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
side_effects updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product	Sponsor	Application	Status	Published
Clindamycin Hydrochloride Tablets RX Clindamycin Hydrochloride Tablet • Oral Label highlights Official documents	Felix Pharmaceuticals Pvt. Ltd.	ANADA 200-813	Approved	Jul 1, 2025
Antirobe® Capsules RX Clindamycin Hydrochloride Capsule • Oral Label highlights Official documents	Zoetis Inc.	NADA 120-161	Approved	Dec 10, 2019
ClindaMed™ Oral Drops RX Clindamycin Liquid • Oral Label highlights Official documents	Bimeda Animal Health Limited	ANADA 200-538	Approved	Oct 2, 2018
Clindamycin Hydrochloride Oral Drops RX Clindamycin Hydrochloride Liquid (Solution) • Oral Label highlights Official documents	First Priority, Inc.	ANADA 200-398	Approved	Dec 27, 2017
Antirobe Aquadrops® RX Clindamycin Hydrochloride Liquid (Solution) • Oral Label highlights Official documents	Zoetis Inc.	NADA 135-940	Approved	Jul 11, 2017
Clindamycin Hydrochloride Oral Liquid RX Clindamycin Hydrochloride Liquid (Solution) • Oral Label highlights Official documents	Cronus Pharma Specialities India Private Ltd.	ANADA 200-193	Approved	May 22, 2017
Clindamycin Hydrochloride Capsules RX Clindamycin Hydrochloride Capsule • Oral Label highlights Official documents	Cronus Pharma Specialities India Private Ltd.	ANADA 200-298	Approved	Jun 1, 2016
ClindaRobe™ RX Clindamycin Hydrochloride Capsule • Oral Label highlights Official documents	Teva Canada Ltd.	ANADA 200-383	W	Jun 1, 2016
Clinsol® RX Clindamycin Hydrochloride Liquid (Solution) • Oral Label highlights Official documents	Virbac AH, Inc.	ANADA 200-291	Approved	Jun 1, 2016
Clintabs® RX Clindamycin Hydrochloride Tablet • Oral Label highlights Official documents	Virbac AH, Inc.	ANADA 200-316	Approved	Jun 1, 2016

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Composition / specifications

25 mg, 75 mg, and 150 mg

Dogs

Indication

Dosage

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

Each capsule contains the equivalent of 25, 75, 150 or 300 milligrams of clindamycin as the hydrated hydrochloride salt.

Dogs

Indication

For the treatment of skin infections (wounds and abscesses) due to susceptible strains of coagulase-positive staphylococci (Staphylococcus aureus or S. intermedius), deep wounds and abscesses due to susceptible strains of Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum, and Clostridium perfringens, dental infections due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens, and osteomyelitis due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens.

Dosage

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied

Composition / specifications

Each mL contains clindamycin hydrochloride equivalent to 25 mg clindamycin.

Dogs

Indication

For the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below:

Dental infections due to Staphylococcus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens.

Osteomyelitis due to Staphylococcus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens.

Dosage

Wounds, abscesses, and dental infections: 2.5 to 15 mg per pound body weight every 12 hours for a maximum of 28 days.

Osteomyelitis: 5.0 to 15 mg/lb body weight every 12 hours for a minimum of 28 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian

Cats

Indication

Dental infections due to Staphylococcus aureus, Staphylococcus intermedius, Streptococcus spp., Clostridium perfringens and Bacteroides fragilis.

Dosage

5.0 to 15.0 mg/lb body weight every 24 hours for a maximum of 14 days

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied

Composition / specifications

Each milliliter of solution contains the equivalent of 25 milligrams (mg) clindamycin as the hydrochloride salt.

Dogs

Indication

Dosage

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Cats

Indication

Dosage

5.0 to 15.0 milligrams per pound of body weight every 24 hours for a maximum of 14 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied

Composition / specifications

Each milliliter of solution contains the equivalent of 25 milligrams (mg) clindamycin as the hydrochloride salt.

Dogs

Indication

For the treatment of skin infections (wounds and abscesses) due to susceptible strains of coagulase-positive staphylococci (Staphylococcus aureus or S. intermedius), deep wounds and abscesses due to susceptible strains of Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum, and Clostridium perfringens, dental infections due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens, and osteomyelitis due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens.

Dosage

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Cats

Indication

Dosage

5.0 to 15.0 milligrams per pound of body weight every 24 hours for a maximum of 14 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied

Composition / specifications

Each milliliter of 8.64 percent alcoholic solution contains the equivalent of 25 milligrams of clindamycin (as the hydrochloride).

Cats

Indication

Dosage

5.0 to 10.0 milligrams per pound of body weight every 24 hours for a maximum of 14 days (11 to 22 milligrams per kilogram of body weight per day).

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Dogs

Indication

Dosage

Osteomyelitis: 5.0 milligrams per pound of body weight every 12 hours for a minimum of 28 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Indication

Dosage

Wounds abscesses, and dental infections: 2.5 milligrams per pound of body weight every 12 hours for a maximum of 28 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

Each capsule contains the equivalent of 25, 75, or 150 milligrams of clindamycin as the hydrated hydrochloride salt.

Dogs

Indication

Dosage

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

Dogs

Indication

For the treatment of skin infections (wounds and abscesses) due to susceptible strains of coagulase-positive staphylococci (Staphylococcus aureus or S. intermedius), deep wounds and abscesses due to susceptible strains of Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum, and Clostridium perfringens, dental infections due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens, and osteomyelitis due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens.

Dosage

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied

Composition / specifications

Each milliliter of solution contains the equivalent of 25 milligrams (mg) clindamycin as the hydrochloride salt.

Dogs

Indication

Dosage

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Cats

Indication

Dosage

5.0 to 15.0 milligrams per pound of body weight every 24 hours for a maximum of 14 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

Each tablet contains the equivalent of 25, 75 or 150 milligrams of clindamycin as the hydrochloride salt.

Dogs

Indication

Dosage

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Usage

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive

Vomiting (1) • Dog Loss of appetite (1) • Dog Drooling (1) • Dog Diarrhea (1) • Dog Decreased appetite (1) • Dog

Showing top 5 for Digestive.

Skin & allergy

Application site hair loss (1) • Cat

Showing top 5 for Skin & allergy.

Behavior

Behavioral disorder (1) • Dog

Showing top 5 for Behavior.

Other

Epidermal collarette (1) • Dog Elevated total bilirubin (1) • Dog Elevated serum alkaline phosphatase (1) • Dog Elevated liver enzymes NOS (1) • Dog Elevated globulins (1) • Dog

Show more (20)

Elevated blood urea nitrogen (1) • Cat Elevated alanine aminotransferase (1) • Dog Electrolyte disorder (1) • Dog Ear pain (1) • Dog Ear irritation (1) • Dog Ear infection NOS (1) • Dog Ear canal inflammation (1) • Dog Dilated pupils (1) • Cat Dermal thickening (1) • Dog Decreased cholesterol (1) • Dog Death by euthanasia (1) • Cat Death (1) • Cat Corneal ulcer (1) • Dog Corneal oedema (1) • Dog Corneal disorder NOS (1) • Dog Conjunctival oedema (1) • Dog Collapse NOS (1) • Dog Application site excoriation (1) • Cat Abnormal menace reflex test (1) • Dog Abnormal cytology (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, ['Chihuahua', 'Dog (unknown)'], Female, 20 week, 2.26 kilogram • Drug: MSK, Oral • Reactions: Icterus, Death, Other abnormal test result NOS, Elevated liver enzymes NOS, Swollen joint… • Outcome: Died

Report ID: USA-USFDACVM-2025-US-074897
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 20.00 Week
Weight: 2.260 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Oral

Reactions Reported:

Icterus Death Other abnormal test result NOS Elevated liver enzymes NOS Swollen joint Localised hair loss Skin lesion NOS Conjunctival oedema Corneal oedema Skin scab Swollen limb Tiredness (lethargy) Loss of appetite Ear infection NOS Local swelling

Outcomes: Died

Dog, Spitz - German Pomeranian, Female, 4 year, 1.633 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Decreased appetite, Vomiting bile, Diarrhea, Electrolyte disorder, Hypoalbuminaemia… • Outcome: Ongoing

Report ID: USA-USFDACVM-2025-US-071574
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 4.00 Year
Weight: 1.633 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown
Form: Unassigned

Reactions Reported:

Decreased appetite Vomiting bile Diarrhea Electrolyte disorder Hypoalbuminaemia Decreased cholesterol Low creatinine Weight loss

Outcomes: Ongoing

Dog, Dog (unknown), Male, 15 year, 14.969 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Head tilt - neurological disorder, Walking difficulty, Vomiting, Skin and tissue infection NOS, General illness… • Outcome: Died

Report ID: USA-USFDACVM-2025-US-071565
Serious AE: Yes
Treated For AE: Yes
Sex: Male
Age: 15.00 Year
Weight: 14.969 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown
Form: Unassigned

Reactions Reported:

Head tilt - neurological disorder Walking difficulty Vomiting Skin and tissue infection NOS General illness Death

Outcomes: Died

Cat, Domestic Shorthair, Female, 15 year, 3.175 kilogram • Drug: MSK, Oral • Reactions: Not eating, Head tilt - ear disorder, Elevated blood urea nitrogen • Outcome: Ongoing

Report ID: USA-USFDACVM-2025-US-072712
Serious AE: No
Treated For AE: Yes
Sex: Female
Age: 15.00 Year
Weight: 3.175 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Oral

Reactions Reported:

Not eating Head tilt - ear disorder Elevated blood urea nitrogen

Outcomes: Ongoing

Dog, ['Terrier (unspecified)', 'Dog (unknown)'], Male, 9 year, 18.14 kilogram • Drug: MSK, Unknown • Reactions: Behavioral disorder (unspecified), Epidermal collarette, Hepatic toxicosis, Dermal thickening, Pyoderma… • Outcome: Died

Report ID: USA-USFDACVM-2025-US-074320
Serious AE: Yes
Treated For AE: Yes
Sex: Male
Age: 9.00 Year
Weight: 18.140 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown

Reactions Reported:

Behavioral disorder (unspecified) Epidermal collarette Hepatic toxicosis Dermal thickening Pyoderma Joint swelling Local swelling Skin ulcer Tiredness (lethargy) Itching Hair loss NOS Death Inappetence

Outcomes: Died

Dog, Terrier - Boston, Male, 11 year, 12.247 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Ear irritation, Polyp, Eye inflammation NOS, Eye irritation, Abnormal cytology… • Outcome: Ongoing

Report ID: USA-USFDACVM-2025-US-070095
Serious AE: Yes
Treated For AE: Yes
Sex: Male
Age: 11.00 Year
Weight: 12.247 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown
Form: Unassigned

Reactions Reported:

Ear irritation Polyp Eye inflammation NOS Eye irritation Abnormal cytology Scratching Medication error NOS Ear pain Ear canal inflammation Corneal disorder NOS Corneal oedema Corneal ulcer Increased intra-ocular pressure

Outcomes: Ongoing

Cat, Male • Drug: MSK, Solution, Oral, Dose: 25 Milligram per ml, Frequency: 2 per day • Reactions: Neurological symptoms NOS • Outcome: Euthanized

Report ID: USA-USFDACVM-2025-US-073374
Serious AE: Yes
Treated For AE: No
Sex: Male

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Oral
Form: Solution
Dose: 25 Milligram per ml
Frequency: 2 per day

Reactions Reported:

Neurological symptoms NOS

Outcomes: Euthanized

Report ID: USA-USFDACVM-2025-US-068424
Serious AE: Yes
Treated For AE: Yes
Sex: Male
Age: 9.00 Year
Weight: 18.140 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown

Reactions Reported:

Outcomes: Died

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

No community reviews yet. Be the first to share your experience.

This medication has not been reviewed by a veterinarian yet.

Medical Disclaimer: The medication details provided on Roxee are for informational purposes only and are not a substitute for professional veterinary advice. Always consult your veterinarian about your pet's specific needs.

Clindamycin

Data freshness

Evidence

Clindamycin

Medication Snapshot

Clindamycin

Indications / Uses

Warnings / Contraindications

Side Effects

FAQ

What species is this commonly shown for?

Does this usually require a prescription?

What dosage forms are listed?

Related Conditions

Source Transparency

Add to My Pet's Meds

Pet Owner Quick Guide

Quick Facts

Warnings / Contraindications

Adverse Reactions

Grouped by Body System

Most Reported Reactions

Documents

Owner handouts

Official label / PI

SPL

FOI

Clindamycin Hydrochloride Tablets

Clindamycin Hydrochloride Tablets

Dogs

Antirobe® Capsules

Antirobe® Capsules

Dogs

ClindaMed™ Oral Drops

ClindaMed™ Oral Drops

<strong>Dogs</strong>

<strong>Cats</strong>

Clindamycin Hydrochloride Oral Drops

Clindamycin Hydrochloride Oral Drops

Dogs

Cats

Antirobe Aquadrops®

Antirobe Aquadrops®

Dogs

Cats

Clindamycin Hydrochloride Oral Liquid

Clindamycin Hydrochloride Oral Liquid

Cats

Dogs

Clindamycin Hydrochloride Capsules

Clindamycin Hydrochloride Capsules

Dogs

ClindaRobe™

ClindaRobe™

Dogs

Clinsol®

Clinsol®

Dogs

Cats

Clintabs®

Clintabs®

Dogs

Clindamycin Hydrochloride SPL

Clindamycin Hydrochloride SPL

CLINTABS SPL

Antirobe SPL

Antirobe Aquadrops SPL

ZydaClin SPL

Clindamycin SPL

FOI Summary oA 200-813 Approved June 27, 2025.pdf

ucm069817.pdf

UCM355629.pdf

ucm061348.pdf

ucm069874.pdf

UCM454278.pdf

N135940_Supp_11_16_89(2).pdf

UCM061610.pdf

UCM061609.pdf

A200193_Org_8_1_1997.pdf

ucm061743.pdf